18 Jul Logomix Biotechnology
Yasunori Aizawa, Ph.D., Co-Founder and Chief Scientific Officer
Oct. 7 | 9:15am | FLW Ballroom G
Tokyo, Japan
(Private)
Logomix is transforming iPSC engineering with Geno-Writing™, a groundbreaking genome engineering platform, and currently focusing on iPSC development for Type 1 Diabetes (T1D) treatment. Geno-Writing™ platform enables precise, large-scale genomic rewriting. This allows bi-allelic modification of loci up to 100kb and stable integration of up to 12 transgenes within 2.5 months, setting a new benchmark in iPSC engineering.
Complementing this, our semi-automated CloneMax system simultaneously creates over 5,000 distinct iPSC lines with varying genome designs, accelerating the identification of optimal therapeutic candidates. This powerful synergy addresses key T1D challenges: achieving robust immune tolerance and significantly enhancing β-cell differentiation and insulin secretion. Logomix’s integrated platforms offer a robust solution for next-generation, allogeneic iPSC-derived cell therapies, promising more effective and widely accessible T1D treatments
